

Date: 24th April, 2020.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Id "BAJAJHCARE", Script Code "539872"

Dear Sir/Madam,

Ref : Your Email dated April 24, 2020 bearing No. L/SURV/ONL/PV/NK/2020-2021/348.
Sub: Clarification on Price Movement.

We are in receipt of the above referred email from BSE Ltd. In this connection we would like to inform you that recently we had received FDA, Gujarat, India approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation for its tablets and the same was duly disclosed and published on the Stock Exchange website for Investors at large on April 17, 2020.

Also we have been regularly informing all the events and information that have a bearing on the operation / performance of the Company including all price sensitive information, as and when required from time to time and there is no pending information to be intimated under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as on date. Therefore, whatever the increase or decrease in share price of the company is purely due to market conditions and absolutely market driven.

Kindly take the same on record.

**For and behalf of Board of Directors of
Bajaj Healthcare Limited**



**Company Secretary
Aakash Keshari**